Literature DB >> 9467938

Role of morphogenetic factors in metastasis of mammary carcinoma cells.

S Meiners1, V Brinkmann, H Naundorf, W Birchmeier.   

Abstract

We have analysed the role of the morphogenetic factors hepatocyte growth factor/scatter factor (HGF), neuregulin and E-cadherin in the process of metastasis and morphogenesis of mammary carcinoma cells. The cDNAs for HGF, neuregulin and E-cadherin were stably expressed in anaplastic human MDA MB 435 carcinoma cells. The altered cells were then injected into the mammary fat pads of nude mice, where they form tumors which can spontaneously metastasize to the lungs. We found that expression of HGF or neuregulin promoted metastasis whereas expression of the cell adhesion molecule E-cadherin was inhibitory. Moreover, expression of E-cadherin reconstituted the ability of the cells to form morphogenetic structures in matrigel cultures in response to HGF. These data demonstrate that HGF and neuregulin, which control branching or lobulo-alveolar morphogenesis of normal breast epithelium, do have metastasis-promoting effects on breast carcinoma cells. Moreover, our results suggest that the differential activities of the two factors can be explained by the degree of epithelial differentiation: induction of morphogenesis requires an intact epithelial adhesion and differentiation system, whereas induction of metastasis is observed when the cells have lost their epithelial characteristics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467938     DOI: 10.1038/sj.onc.1201486

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

Review 1.  Cadherin junctions in mammary tumors.

Authors:  M J Wheelock; A P Soler; K A Knudsen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

2.  Further evidence to support the melanocytic origin of MDA-MB-435.

Authors:  G Ellison; T Klinowska; R F R Westwood; E Docter; T French; J C Fox
Journal:  Mol Pathol       Date:  2002-10

Review 3.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

4.  Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells.

Authors:  R Mukhopadhyay; R L Theriault; J E Price
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

Review 5.  Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis.

Authors:  Kenna R Mills Shaw; Carolyn N Wrobel; Joan S Brugge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

Review 6.  Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling.

Authors:  Julian Heuberger; Walter Birchmeier
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

7.  Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.

Authors:  Yu Deng; Hui Deng; Jing Liu; Gangwen Han; Stephen Malkoski; Bolin Liu; Rui Zhao; Xiao-Jing Wang; Qinghong Zhang
Journal:  Mol Carcinog       Date:  2011-06-16       Impact factor: 4.784

8.  EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.

Authors:  Jerrica L Breindel; Jonathan W Haskins; Elizabeth P Cowell; Minghui Zhao; Don X Nguyen; David F Stern
Journal:  Cancer Res       Date:  2013-06-21       Impact factor: 12.701

9.  Common mechanism of pathogenesis in various types of metastatic osteosarcoma.

Authors:  Dongqi Wang; Zongrang Song; Zhan Wang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

10.  Biogenesis and function of mouse mammary epithelium depends on the presence of functional alpha-catenin.

Authors:  Rashmi V Nemade; Brian Bierie; Masahiro Nozawa; Celine Bry; Gilbert H Smith; Valera Vasioukhin; Elaine Fuchs; Lothar Hennighausen
Journal:  Mech Dev       Date:  2004-01       Impact factor: 1.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.